# Tesamorelin / Ipamorelin Blend

> This blend pairs tesamorelin, a stabilized GHRH analog studied and approved in some jurisdictions for reducing excess visceral fat in a specific clinical population, with ipamorelin, a selective ghrelin-receptor agonist. Tesamorelin has a comparatively strong individual evidence base from randomized clinical trials focused on visceral adipose tissue and body composition, while ipamorelin is added for its complementary GH-pulse-amplifying effect. The combined blend itself, used outside tesamorelin's approved population and indication, has not been studied in controlled trials. It is discussed mainly in the context of body composition and visceral fat research. It is not approved for the general population or for this combined use.

- URL: https://www.lifeconverted.com/peptides/tesamorelin-ipamorelin-blend
- Also known as: Tesa/Ipa Blend
- Primary category: GH Blends
- Effectiveness rank: #16 in Weight Management; #999 in Growth Hormone Peptides; #999 in GH Releasing Hormones; #2 in GH Blends
- Evidence level: Well studied
- Route: Subcutaneous (Injected subcutaneously into the abdomen, typically once daily given tesamorelin's short individual half-life; both peptides are commonly combined in one syringe.)
- Dose range: 1,500-3,000 mcg
- Dose tiers: low 1500 mcg; moderate 2200 mcg; high 3000 mcg
- Half-life: Tesamorelin is reported at approximately 25-40 minutes; ipamorelin at approximately 2 hours. Both are comparatively short-acting, which supports once-daily dosing.
- Timing: ~30 min before bed, empty stomach
- Cycle: 12-16 weeks on, 4-6 weeks off (Tesamorelin's studied clinical protocols often run longer than typical secretagogue cycles; shorter informal cycles are commonly referenced outside clinical use.)
- Storage: Refrigerate after reconstitution (2-8°C); use within 2-4 weeks is commonly recommended.

## Mechanism of action

Tesamorelin stimulates the GHRH receptor with a pharmacokinetic profile designed for consistent daily dosing, and its clinical evidence base centers on reductions in visceral adipose tissue via the GH/IGF-1 axis. Ipamorelin contributes an independent ghrelin-receptor-mediated GH pulse with a comparatively selective side-effect profile. The pairing is described as combining tesamorelin's studied visceral-fat-focused signaling with a broader amplification of the overall GH pulse from ipamorelin.

## Reported benefits

- Associated with visceral fat reduction based on tesamorelin's studied effects
- Supports body composition changes
- Amplifies overall growth-hormone pulse
- General fat-metabolism research interest

## Reported side effects

- Injection site reactions
- Joint or muscle discomfort
- Water retention
- Mild elevation in blood glucose (associated with GH-axis stimulation)
- Headache

## Common protocols

- Visceral Fat Reduction
- Body Composition
- GH Optimization

## Stacking notes

Tesamorelin's individual evidence base is comparatively strong for visceral fat reduction; the combination with ipamorelin has not itself been evaluated in controlled trials.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer